Biotech of the Week: Affibody and its Super antibodies from Scandinavia

06/05/2016 - 2 minutes

From North Israel, we once again depart North towards Scandinavia to visit Sweden. On one of the several islands that make Stockholm a very particular and special European capital, our Biotech of the week Affibody has its headquarters.


City: Stockholm (Sweden) – (actually just down the road from the Karolinska Institute)

Founded: 1998

Employees: 22 (as of 11/2015)

Financial Data: €5.3M Revenues (in 2015)

CEO: David Bejker


Mission: Affibody’s key platform is Affibody molecules, a novel class of antibody mimetics which due to their size surpass most monoclonal antibodies (mAbs) and antibody fragments in performance.

They are small sized (only 58 amino acid residues), extremely stable, low production cost, low background binding and a favourable patent situation.

Currently it is developing 4 proprietary programs: 3 of them are therapeutically focused and target the prevention of Alzheimer’s disease,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member